Zenith Capital (Zenith Capital) Preferred Dividends : $0.00 Mil (TTM As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Zenith Capital's preferred dividends for the three months ended in . 20 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in . 20 was $0.00 Mil.

Zenith Capital Preferred Dividends Historical Data

The historical data trend for Zenith Capital's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Preferred Dividends Chart

Zenith Capital Annual Data

Trend

Preferred Dividends

Zenith Capital Quarterly Data

Preferred Dividends

Zenith Capital Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Zenith Capital (OTCPK:ZHCLF) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines